Topical thalidomide gel in oral chronic GVHD and role of in situ cytokine expression in monitoring biological activity

Bone Marrow Transplant. 2013 Apr;48(4):610-1. doi: 10.1038/bmt.2012.178. Epub 2012 Sep 24.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, N.I.H., Intramural

MeSH terms

  • Administration, Topical
  • Adult
  • Chronic Disease
  • Cytokines / biosynthesis*
  • Double-Blind Method
  • Female
  • Gels
  • Gene Expression Regulation / drug effects*
  • Graft vs Host Disease* / drug therapy
  • Graft vs Host Disease* / metabolism
  • Graft vs Host Disease* / pathology
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Immunosuppressive Agents / administration & dosage*
  • Male
  • Middle Aged
  • Mouth Diseases* / drug therapy
  • Mouth Diseases* / metabolism
  • Mouth Diseases* / pathology
  • Thalidomide / administration & dosage*
  • Transplantation, Homologous

Substances

  • Cytokines
  • Gels
  • Immunosuppressive Agents
  • Thalidomide

Associated data

  • ClinicalTrials.gov/NCT00075023